April 23, 2019
WELLESLEY, Mass., April 23, 2019–Rapid adoption in drug discovery, research and screening is helping to boost growth in the bioprinting market, according to a report by BCC Research, “Current Bioprinting Prospects and Future Innovations.”
The global bioprinting market expects to see a compound annual growth rate (CAGR) of 35.4% through 2024, when it could be worth $1.4 billion.
“Bioprinting has found applications in several fields, including tissue engineering and regenerative medicine, organ transplantation, drug and toxicity testing, high-throughput assays and cancer research,” notes report author Dr. Kamna Jhamb. “Many kinds of tissues, particularly those that do not need vascularization or are hollow or thin tissues, have been successfully bioprinted. Examples include bone tissues, cartilage tissue, liver tissue, skin tissues, among others.”
Challenges Include Lack of Skilled Labor, High Equipment Costs
A number of factors are conspiring to restrain market growth. Chief among those is a lack of workers who can operate 3D bioprinting equipment. Further, with some printers costing up to $200,000, research-fund-limited laboratories are not always able to afford them. Additionally, technological challenges limit application of these units and successful fabrication of biological 3D tissue constructs.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at email@example.com.
Current Bioprinting Prospects and Future Innovations( BIO176A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.